<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 39.96?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Cancer Manag Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Cancer Manag Res</journal-id>
    <journal-id journal-id-type="publisher-id">CMAR</journal-id>
    <journal-id journal-id-type="pmc">cancmanres</journal-id>
    <journal-title-group>
      <journal-title>Cancer Management and Research</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1179-1322</issn>
    <publisher>
      <publisher-name>Dove</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">6817837</article-id>
    <article-id pub-id-type="publisher-id">215586</article-id>
    <article-id pub-id-type="doi">10.2147/CMAR.S215586</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Methodology</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>OSacc: Gene Expression-Based Survival Analysis Web Tool For Adrenocortical Carcinoma</article-title>
      <alt-title alt-title-type="running-authors">Xie et al</alt-title>
      <alt-title alt-title-type="running-title">Xie et al</alt-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6825-9690</contrib-id>
        <name>
          <surname>Xie</surname>
          <given-names>Longxiang</given-names>
        </name>
        <xref ref-type="aff" rid="AFF0001">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Qiang</given-names>
        </name>
        <xref ref-type="aff" rid="AFF0001">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Nan</surname>
          <given-names>Fangmei</given-names>
        </name>
        <xref ref-type="aff" rid="AFF0001">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ge</surname>
          <given-names>Linna</given-names>
        </name>
        <xref ref-type="aff" rid="AFF0001">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5683-929X</contrib-id>
        <name>
          <surname>Dang</surname>
          <given-names>Yifang</given-names>
        </name>
        <xref ref-type="aff" rid="AFF0001">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Sun</surname>
          <given-names>Xiaoxiao</given-names>
        </name>
        <xref ref-type="aff" rid="AFF0001">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Ning</given-names>
        </name>
        <xref ref-type="aff" rid="AFF0001">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Dong</surname>
          <given-names>Huan</given-names>
        </name>
        <xref ref-type="aff" rid="AFF0001">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Han</surname>
          <given-names>Yali</given-names>
        </name>
        <xref ref-type="aff" rid="AFF0001">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Guosen</given-names>
        </name>
        <xref ref-type="aff" rid="AFF0001">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhu</surname>
          <given-names>Wan</given-names>
        </name>
        <xref ref-type="aff" rid="AFF0002">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Guo</surname>
          <given-names>Xiangqian</given-names>
        </name>
        <xref ref-type="corresp" rid="AN0001"/>
        <xref ref-type="aff" rid="AFF0001">1</xref>
      </contrib>
      <aff id="AFF0001"><label>1</label><institution>Bioinformatics Department of Predictive Medicine, Institute of Biomedical Informatics, Cell Signal Transduction Laboratory, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Software, School of Basic Medical Sciences, Henan University</institution>, <addr-line>Kaifeng</addr-line><addr-line>475004</addr-line>, <country>People’s Republic of China</country></aff>
      <aff id="AFF0002"><label>2</label><institution>Department of Anesthesia, Stanford University</institution>, <addr-line>Stanford</addr-line>, <addr-line>CA</addr-line>, <country>USA</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="AN0001">Correspondence: Xiangqian Guo <institution>Bioinformatics Department of Predictive Medicine, Institute of Biomedical Informatics, Cell Signal Transduction Laboratory, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Software, School of Basic Medical Sciences, Henan University</institution>, <addr-line>Kaifeng</addr-line><addr-line>475004</addr-line>, <country>People’s Republic of China</country><phone>Tel +86-371-23880585</phone> Email xqguo@henu.edu.cn</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>24</day>
      <month>10</month>
      <year>2019</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2019</year>
    </pub-date>
    <volume>11</volume>
    <fpage>9145</fpage>
    <lpage>9152</lpage>
    <history>
      <date date-type="received">
        <day>14</day>
        <month>5</month>
        <year>2019</year>
      </date>
      <date date-type="accepted">
        <day>02</day>
        <month>10</month>
        <year>2019</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2019 Xie et al.</copyright-statement>
      <copyright-year>2019</copyright-year>
      <copyright-holder>Xie et al.</copyright-holder>
      <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
        <license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <title>Abstract</title>
      <p>Gene expression profiling data with long-term clinical follow-up information are great resources to screen, develop, evaluate and validate prognostic biomarkers in translational cancer research. However, an easy-to-use interactive online tool is needed to analyze these profiling and clinical data. In the current work, we developed OSacc (Online consensus Survival analysis of ACC), a web tool that provides rapid and user-friendly survival analysis based on seven independent transcriptomic profiles with long-term clinical follow-up information of 259 ACC patients gathered from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. OSacc allows researchers and clinicians to evaluate the prognostic value of genes of interest by Kaplan–Meier (KM) survival plot with hazard ratio (HR) and log-rank test in ACC. OSacc is freely available at <underline><ext-link ext-link-type="uri" xlink:href="http://bioinfo.henu.edu.cn/ACC/ACCList.jsp">http://bioinfo.henu.edu.cn/ACC/ACCList.jsp</ext-link></underline>.</p>
    </abstract>
    <kwd-group kwd-group-type="author">
      <title>Keywords</title>
      <kwd>ACC</kwd>
      <kwd>prognostic marker</kwd>
      <kwd>over survival</kwd>
      <kwd>web tool</kwd>
      <kwd>KM plot</kwd>
    </kwd-group>
    <counts>
      <fig-count count="3"/>
      <table-count count="2"/>
      <ref-count count="29"/>
      <page-count count="8"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="S0001">
    <title>Introduction</title>
    <p>Adrenocortical carcinoma (ACC) is a type of rare and aggressive malignancy with a poor 5-year over survival rate which is below 40%.<xref rid="CIT0001" ref-type="bibr">1</xref> Due to the limited treatment options for patients with locally advanced ACC and high risk of relapse even after major operative resection, identifying new prognostic biomarkers and therapeutic targets to improve the therapies for ACC patients is very important.<xref rid="CIT0002" ref-type="bibr">2</xref>–<xref rid="CIT0004" ref-type="bibr">4</xref> In recent decades, clinical bio-samples have been extensively analyzed by gene microarray or RNA-Seq technologies.<xref rid="CIT0005" ref-type="bibr">5</xref>,<xref rid="CIT0006" ref-type="bibr">6</xref> Although numerous public transcriptomic datasets with clinical information are available, it is very difficult for researchers or clinicians without bioinformatics training to quickly assess the prognostic value of putative biomarkers. Because getting, processing, filtering, and building survival model of large gene expression datasets are time-consuming and need professional programming skills. In addition, the reported prognostic biomarkers such as <italic>GLUT1</italic><xref rid="CIT0007" ref-type="bibr">7</xref> and <italic>PTTG1</italic><xref rid="CIT0008" ref-type="bibr">8</xref> in ACC need to be independently validated in multi-cohorts of different populations before being translated into clinical use.</p>
    <p>To build a user-friendly tool that contains ACC gene expression profiles with clinical follow-up data to perform online ACC prognosis analysis, we collected the transcriptomic profiles and clinical information of 259 ACC patients from seven independent cohorts derived from TCGA and GEO to establish OSacc. OSacc is a web-based portal providing survival analysis and risk assessment in ACC datasets using gene symbol as input. This tool offers biomedical researchers and clinicians lacking bioinformatics training to quickly identify putative prognostic biomarkers from gene expression data in ACC. This web tool is available through <underline><ext-link ext-link-type="uri" xlink:href="http://bioinfo.henu.edu.cn/ACC/ACCList.jsp">http://bioinfo.henu.edu.cn/ACC/ACCList.jsp</ext-link></underline>.</p>
  </sec>
  <sec id="S0002">
    <title>Materials And Methods</title>
    <sec id="S0002-S2001">
      <title>Data Collection</title>
      <p>Messenger RNA (mRNA) expression profiling data with patients’ survival information were collected from GEO and TCGA. To gather the data from GEO, the searching keywords “Adrenocortical carcinoma” or “ACC” and “survival” were used in GEO database. The obtained TCGA data are Level 3 RNAseq data with clinical information of ACC patients. The detailed information of above data from GEO and TCGA are described in <xref rid="T0001" ref-type="table">Table 1</xref>. Only dataset with ≥20 ACC samples was included in this study.<table-wrap id="T0001" orientation="landscape" position="float"><label>Table 1</label><caption><p>Clinical Characteristics Of The ACC Patients Used In OSacc</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">ID</th><th rowspan="1" colspan="1">Platform</th><th rowspan="1" colspan="1">Sample Type</th><th rowspan="1" colspan="1">Number Of Samples</th><th rowspan="1" colspan="1">Death Events</th><th rowspan="1" colspan="1">Median OverAll Survival (Months)</th><th rowspan="1" colspan="1">Ages (Years)</th><th rowspan="1" colspan="1">Gender (M/F)</th><th rowspan="1" colspan="1">Stage (I/II/III/IV)</th><th rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">GSE10927</td><td rowspan="1" colspan="1">GPL570</td><td rowspan="1" colspan="1">Primary tumor</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">19.02 (8.85–32.83)</td><td rowspan="1" colspan="1">7/17 (25.9%/74.1%)</td><td rowspan="1" colspan="1">2/11/3/8 (8.3%/45.8%/12.5%/33.3%)</td><td rowspan="1" colspan="1">7/17 (25.9%/74.1%)</td><td rowspan="1" colspan="1"><xref rid="CIT0020" ref-type="bibr">20</xref></td></tr><tr><td rowspan="1" colspan="1">GSE19750</td><td rowspan="1" colspan="1">GPL570</td><td rowspan="1" colspan="1">Primary tumor</td><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">36.00 (19.35–103.75)</td><td rowspan="1" colspan="1">11/11 (50%/50%)</td><td rowspan="1" colspan="1">1/7/1/4 (7.7%/53.8/7.7%/30.8%)</td><td rowspan="1" colspan="1">11/11 (50%/50%)</td><td rowspan="1" colspan="1"><xref rid="CIT0008" ref-type="bibr">8</xref></td></tr><tr><td rowspan="1" colspan="1">GSE33371</td><td rowspan="1" colspan="1">GPL570</td><td rowspan="1" colspan="1">Primary tumor</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">15.48 (8.4–61.88)</td><td rowspan="1" colspan="1">7/16 (30.4%/69.6%)</td><td rowspan="1" colspan="1">2/10/3/8 (8.7%/43.5%/13%/34.8%)</td><td rowspan="1" colspan="1">7/16 (30.4%/69.6%)</td><td rowspan="1" colspan="1"><xref rid="CIT0021" ref-type="bibr">21</xref></td></tr><tr><td rowspan="1" colspan="1">GSE49280</td><td rowspan="1" colspan="1">GPL8490</td><td rowspan="1" colspan="1">Primary tumor</td><td rowspan="1" colspan="1">44</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">51.85 (20.70–112.4)</td><td rowspan="1" colspan="1">8/36 (18.2%/81.8%)</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">8/36 (18.2%/81.8%)</td><td rowspan="1" colspan="1"><xref rid="CIT0022" ref-type="bibr">22</xref></td></tr><tr><td rowspan="1" colspan="1">GSE76019</td><td rowspan="1" colspan="1">GPL13158</td><td rowspan="1" colspan="1">Primary tumor</td><td rowspan="1" colspan="1">34</td><td rowspan="1" colspan="1">12<sup>#</sup></td><td rowspan="1" colspan="1">26.25 (17.59–52.59)</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">10/7/10/7 (29.4%/20.6%/29.4%/20.65)</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1"><xref rid="CIT0023" ref-type="bibr">23</xref></td></tr><tr><td rowspan="1" colspan="1">GSE76021</td><td rowspan="1" colspan="1">GPL96</td><td rowspan="1" colspan="1">Primary tumor</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">11*</td><td rowspan="1" colspan="1">21.45 (9.21–99.26)</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">5/5/8/2 (25%/25%/40%/10%)</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1"><xref rid="CIT0023" ref-type="bibr">23</xref></td></tr><tr><td rowspan="1" colspan="1">TCGA</td><td rowspan="1" colspan="1">RNAseq</td><td rowspan="1" colspan="1">Primary tumor</td><td rowspan="1" colspan="1">92</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">31.20 (16.80–58.59)</td><td rowspan="1" colspan="1">60/32 (65.2%/34.8%)</td><td rowspan="1" colspan="1">9/44/19/18 (10%/48.9%/21.1%/20%)</td><td rowspan="1" colspan="1">60/32 (65.2%/34.8%)</td><td rowspan="1" colspan="1"><xref rid="CIT0024" ref-type="bibr">24</xref></td></tr><tr><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">259</td><td rowspan="1" colspan="1">123</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">93/112 (45.4%/54.6%)</td><td rowspan="1" colspan="1">29/84/44/47 (14.3%/41.4%/21.7%/23.2%)</td><td rowspan="1" colspan="1">93/112 (45.4%/54.6%)</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold><sup>#</sup>EFS event; *PFS event.</p></fn><fn><p><bold>Abbreviations:</bold> TCGA, TCGA-ACC; NA, not available; M, male; F, female.</p></fn></table-wrap-foot></table-wrap>
</p>
    </sec>
    <sec id="S0002-S2002">
      <title>OSacc Web Tool</title>
      <p>OSacc is developed as previously described with minor modifications.<xref rid="CIT0009" ref-type="bibr">9</xref>–<xref rid="CIT0013" ref-type="bibr">13</xref> In brief, OSacc contains two main components: storage and data analysis. A Java implementation was used to construct OSacc. OSacc used SQL Server database to provide the storage and management of the gene expression profiles and clinical follow-up data for ACC, and applied the Browser/Server architecture network management system to manage database. R package “survival” was used to perform Cox regression analysis to calculate the hazard ratio, 95% confidence intervals and p-value. R packages “survminer” and “ggplot2” were applied to plot the Kaplan–Meier curves (<underline><ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=215586.pdf">Figure S1</ext-link></underline>). The web-based ﻿interface is shown in <xref rid="F0001" ref-type="fig">Figure 1</xref>.<fig id="F0001" fig-type="figure" orientation="portrait" position="float"><label>Figure 1</label><caption><p>The web interface of OSacc.</p></caption><graphic content-type="print-only" xlink:href="CMAR-11-9145-g0001"/></fig></p>
    </sec>
    <sec id="S0002-S2003">
      <title>Searching Previous Known Prognostic Biomarkers In ACC</title>
      <p>All known ACC prognostic biomarkers are searched in PubMed using the combined keywords “ACC” or “Adrenocortical carcinoma”, “prognostic” and “biomarkers”. Seven prognostic biomarkers were selected from 165 publications. The prognostic values of these previously reported prognostic biomarkers were determined in the combined datasets of ACC patients in OSacc.</p>
    </sec>
    <sec id="S0002-S2004">
      <title>Statistical Analysis</title>
      <p>GraphPad Prism 8.0 (GraphPad Inc., La Jolla, CA, USA) software was used for statistical analysis. The mRNA expression of <italic>CENPF</italic> in ACC cancer tissues was compared with that in normal tissues, using a Wilcoxon rank-sum test (also called Mann–Whitney test) to calculate a <italic>p</italic> value. A value of <italic>p</italic>&lt;0.05 was considered statistically significant.</p>
    </sec>
  </sec>
  <sec id="S0003">
    <title>Results</title>
    <sec id="S0003-S2001">
      <title>Clinical Characteristics Of ACC Datasets Used In OSacc</title>
      <p>To obtain the microarray or RNAseq data of ACC with clinical survival information, we searched the GEO and TCGA database. Finally, a total of 259 ACC cases including 167 samples from 6 GEO datasets and 92 samples from TCGA datasets were collected. All of these samples are primary tumors. The median age of these patients is 48 years old and the ratio of male to female is 1:1.2. Two hundred and five patients have OS (overall survival), 34 patients have EFS (event-free survival), and 20 patients have PFS (progression-free survival). A summary of above ACC cohorts is shown in <xref rid="T0001" ref-type="table">Table 1</xref>.</p>
    </sec>
    <sec id="S0003-S2002">
      <title>Application Of OSacc Web Tool</title>
      <p>To measure the correlation between the gene of interest and survival rate, Kaplan–Meier plot was applied in OSacc. To use OSacc, users first input the query gene symbol, choose either one dataset or combined datasets, then select the median or other appropriate cutoff value of gene expression to categorize the ACC patients (<xref rid="F0002" ref-type="fig">Figure 2A</xref>). Combined datasets mean that each cohort was divided separately into strata by selecting the appropriate cutoff value, which are then pooled for survival analysis. Next, users select the specific survival terms including OS, EFS, PFS, DFI (disease-free interval), and PFI (progression-free interval) (<xref rid="F0002" ref-type="fig">Figure 2B</xref>). Users may be also interested in limiting their analysis in a subgroup of patients by selecting the optional confounding clinical factors such as TNM, gender, and race (<xref rid="F0002" ref-type="fig">Figure 2C</xref>–<xref rid="F0002" ref-type="fig">F</xref>). Finally, users click the “Kaplan–Meier plot” button, and the prognostic (Kaplan–Meier, KM) plots with HR, 95% CI and <italic>p</italic> value will be shown on the output web page. <italic>P</italic> value of all genes calculated by Univariate Cox analysis in OSacc are shown in <underline><ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=215586.xlsx">Table S1</ext-link></underline>.<fig id="F0002" fig-type="figure" orientation="portrait" position="float"><label>Figure 2</label><caption><p>The screenshot of input parameter in OSacc (<bold>A</bold>–<bold>F</bold>). The options of main input parameters and clinical factors of OSacc.</p></caption><graphic content-type="print-only" xlink:href="CMAR-11-9145-g0002"/></fig></p>
    </sec>
    <sec id="S0003-S2003">
      <title>Validation Of Previously Published ACC Prognostic Biomarkers</title>
      <p>To evaluate the performance of OSacc, the prognostic values of 7 ACC prognostic biomarkers were collected from PubMed (shown in <xref rid="T0002" ref-type="table">Table 2</xref>), these 7 reported prognostic biomarkers include 4 unfavorable and 3 favorable ones. To test the OSacc functions, OS was selected as survival term and analyzed in the combined datasets. The cutoff value of splitting the patients was set as upper 25% vs lower 75%. The calculated HR (hazard ratio) and <italic>p</italic> value of these prognostic biomarkers are shown in <xref rid="T0002" ref-type="table">Table 2</xref>. The analysis results in OSacc showed that the prognostic performances of 5 genes (i.e. <italic>GLUT1, PTTG1, MCT2, RARRES2</italic> and <italic>Mki67</italic>) are in accordance with previous reports, while prognostic values of two genes (i.e. <italic>MCT1</italic> and <italic>IGFBP2</italic>) are not the same as previously reported.<table-wrap id="T0002" orientation="portrait" position="float"><label>Table 2</label><caption><p>Validation Of The 7 Previous Reported Prognostic Biomarkers In OSacc</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Gene Symbol</th><th colspan="5" rowspan="1">Literature Data</th><th colspan="3" rowspan="1">OSacc Data</th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">N</th><th rowspan="1" colspan="1">Survival</th><th rowspan="1" colspan="1">Prognostic Value</th><th rowspan="1" colspan="1">Method</th><th rowspan="1" colspan="1">Reference</th><th rowspan="1" colspan="1">HR (95% CI)</th><th rowspan="1" colspan="1"><italic>p</italic>-Value</th><th rowspan="1" colspan="1">Validation Results</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">GLUT1</td><td rowspan="1" colspan="1">130</td><td rowspan="1" colspan="1">OS</td><td rowspan="1" colspan="1">Unfavorable</td><td rowspan="1" colspan="1">IHC</td><td rowspan="1" colspan="1"><xref rid="CIT0007" ref-type="bibr">7</xref></td><td rowspan="1" colspan="1">7.158 (3.135–16.342)</td><td rowspan="1" colspan="1">&lt;0.0001</td><td rowspan="1" colspan="1">√</td></tr><tr><td rowspan="1" colspan="1">PTTG1</td><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">OS</td><td rowspan="1" colspan="1">Unfavorable</td><td rowspan="1" colspan="1">Western blot</td><td rowspan="1" colspan="1"><xref rid="CIT0008" ref-type="bibr">8</xref></td><td rowspan="1" colspan="1">2.391 (1.562–3.661)</td><td rowspan="1" colspan="1">&lt;0.0001</td><td rowspan="1" colspan="1">√</td></tr><tr><td rowspan="1" colspan="1">MCT2</td><td rowspan="1" colspan="1">78</td><td rowspan="1" colspan="1">OS</td><td rowspan="1" colspan="1">Favorable</td><td rowspan="1" colspan="1">IHC</td><td rowspan="1" colspan="1"><xref rid="CIT0025" ref-type="bibr">25</xref></td><td rowspan="1" colspan="1">0.202 (0.044–0.926)</td><td rowspan="1" colspan="1">0.0395</td><td rowspan="1" colspan="1">√</td></tr><tr><td rowspan="1" colspan="1">MCT1</td><td rowspan="1" colspan="1">78</td><td rowspan="1" colspan="1">OS</td><td rowspan="1" colspan="1">Favorable</td><td rowspan="1" colspan="1">IHC</td><td rowspan="1" colspan="1"><xref rid="CIT0025" ref-type="bibr">25</xref></td><td rowspan="1" colspan="1">1.617 (0.912–2.866)</td><td rowspan="1" colspan="1">0.1001</td><td rowspan="1" colspan="1">×</td></tr><tr><td rowspan="1" colspan="1">RARRES2</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">OS</td><td rowspan="1" colspan="1">Favorable</td><td rowspan="1" colspan="1">qPCR</td><td rowspan="1" colspan="1"><xref rid="CIT0026" ref-type="bibr">26</xref></td><td rowspan="1" colspan="1">0.423 (0.243–0.736)</td><td rowspan="1" colspan="1">0.0023</td><td rowspan="1" colspan="1">√</td></tr><tr><td rowspan="1" colspan="1">IGFBP2</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">OS</td><td rowspan="1" colspan="1">Favorable</td><td rowspan="1" colspan="1">ELISA</td><td rowspan="1" colspan="1"><xref rid="CIT0027" ref-type="bibr">27</xref></td><td rowspan="1" colspan="1">1.700 (1.057–2.734)</td><td rowspan="1" colspan="1">0.0286</td><td rowspan="1" colspan="1">×</td></tr><tr><td rowspan="1" colspan="1">Mki67</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">OS</td><td rowspan="1" colspan="1">Unfavorable</td><td rowspan="1" colspan="1">IHC</td><td rowspan="1" colspan="1"><xref rid="CIT0028" ref-type="bibr">28</xref></td><td rowspan="1" colspan="1">3.051 (1.997–4.661)</td><td rowspan="1" colspan="1">&lt;0.0001</td><td rowspan="1" colspan="1">√</td></tr><tr><td rowspan="1" colspan="1">Mki67</td><td rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">OS</td><td rowspan="1" colspan="1">Unfavorable</td><td rowspan="1" colspan="1">IHC</td><td rowspan="1" colspan="1"><xref rid="CIT0029" ref-type="bibr">29</xref></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p><bold>Abbreviations:</bold> N, number; OS, overall survival; HR, hazard ratio; CI, confidence intercal; DSS, disease specific survival; DFS, disease free survival; RFS, recurrence free survival; MFS, metastasis free survival; PFS, progression free survival.</p></fn></table-wrap-foot></table-wrap>
</p>
    </sec>
    <sec id="S0003-S2004">
      <title>Discovery Of Putative Prognostic Biomarkers In OSacc</title>
      <p>In addition to validating the reported prognostic markers in independent clinical datasets, OSacc also can be employed to discover novel prognostic markers in ACC. According to the results of univariate Cox analysis in datasets of TCGA, GSE10927, GSE19750 and GSE33371, we selected the genes with <italic>p</italic> value consistently less than 0.05 in multiple datasets for following screening of potential prognostic biomarkers. <italic>CENPF</italic> (Centromere protein F), a key protein associated with the centromere-kinetochore complex, satisfies this criterion. <italic>CENPF</italic> plays a crucial role in chromosomal segregation during mitosis, and its overexpression has been previously reported in several types of solid tumors. Dai et al found that <italic>CENPF</italic> is highly expressed in HCC (Hepatocellular carcinoma) compared to control tissues, and its overexpression is significantly related with serum AFP, advanced differentiation stage and a shorter OS.<xref rid="CIT0014" ref-type="bibr">14</xref> In addition, functional experiments demonstrated that downregulation of <italic>CENPF</italic> inhibits the cell proliferation, formation of colonies and induces tumor growth in nude mice, suggesting its critical role in driving HCC tumorigenesis.<xref rid="CIT0014" ref-type="bibr">14</xref> In 2018, Shahid et al demonstrated that <italic>CENPF</italic> can regulate PC (Prostate cancer) metabolism by modulating pyruvate kinase M2 phosphorylation signaling.<xref rid="CIT0015" ref-type="bibr">15</xref> A recent study showed that downregulation of <italic>CENPF</italic> can change the global metabolic profiles of PC cells and inhibit cell proliferation, indicating that <italic>CENPF</italic> may be a vital regulator of PC metabolism.<xref rid="CIT0016" ref-type="bibr">16</xref> Data-mining of gene expression profile from 4 GEO datasets (GSE10927, GSE12368, GSE90713 and GSE33371) using non-parametric statistical method showed that <italic>CENPF</italic> expression is significantly up-regulated in ACC tissues compared with normal control tissues (<underline><ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=215586.pdf">Figure S2A</ext-link></underline>–<underline><ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=215586.pdf">D</ext-link></underline>), suggesting that <italic>CENPF</italic> may be linked to pathological process in ACC.</p>
      <p>Using OSacc, we firstly found that patients with high expressing <italic>CENPF</italic> had worse OS, while the low expression of <italic>CENPF</italic> group had better OS in TCGA (HR: 10.498, 95% CI: 4.509–24.440, <italic>p</italic>&lt;0.0001), GSE10927 (HR: 6.990, 95% CI: 2.031–24.060, <italic>p</italic>=0.0020), GSE19750 (HR: 3.738, 95% CI: 1.047–14.349, <italic>p</italic>=0.042), and GSE33371 datasets (HR: 5.075, 95% CI: 1.568–16.420, <italic>p</italic>=0.007) (<xref rid="F0003" ref-type="fig">Figure 3A</xref>–<xref rid="F0003" ref-type="fig">D</xref>). Not surprisingly, in the combined datasets of TCGA, GSE10927, GSE19750 and GSE33371, high <italic>CENPF-</italic>expressing group also showed poor OS (HR: 5.636, 95% CI: 3.414–9.303, <italic>p</italic>&lt;0.0001) (<xref rid="F0003" ref-type="fig">Figure 3E</xref>), suggesting that <italic>CENPF</italic> is a novel unfavorable prognostic biomarker for OS in ACC. The KM plot cannot be shown in the other three datasets, because GSE49280 does not have the probe for <italic>CENPF</italic>, GSE76019 and GSE76021 do not have OS items.<fig id="F0003" fig-type="figure" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Kaplan–Meier plots for high (green) and low (red) <italic>CENPF</italic>-expressing ACC groups in TCGA (<bold>A</bold>), GSE10927 (<bold>B</bold>), GSE19750 (<bold>C</bold>), GSE33371 (<bold>D</bold>) and combined datasets (<bold>E</bold>). Confidence intervals (CI, 95%) and log-rank <italic>p</italic>-values are as shown. The x-axis represents survival time and the y-axis represents survival rate.</p></caption><graphic content-type="print-only" xlink:href="CMAR-11-9145-g0003"/></fig></p>
    </sec>
  </sec>
  <sec id="S0004">
    <title>Discussion</title>
    <p>In this study, we developed a prognosis analysis web tool OSacc that comprises published transcriptomic datasets with clinical information for ACC, and provides survival analysis of ACC patients based on gene expression. The performance of OSacc has been evaluated by seven reported prognostic biomarkers, and the test results showed that 71% (5 of 7) of these reported prognostic biomarkers were confirmed to be prognostic significant in OSacc. The reasons for the insignificance of the 2 genes in OSacc may be due to the use of different detection level/method (ELISA in literature) and data from different ethnic groups.</p>
    <p>Because of the importance of prognostic biomarker development in cancers, a couple of prognostic web tools have been developed, such as Proggene,<xref rid="CIT0017" ref-type="bibr">17</xref> OncoLnc<xref rid="CIT0018" ref-type="bibr">18</xref> and cBioportral.<xref rid="CIT0019" ref-type="bibr">19</xref> Prognene is good in performing an extensive survey of prognosis in general cancer types, however it has limited cases of ACCs. OncoLnc was developed to assess the prognostic significance of non-coding genes but not the coding gene. More importantly, <italic>OSacc</italic> has integrated seven ACC cohorts and incorporated the clinical covariates including TNM, gender and race to provide more informative survival plots to the researchers. The different features between OSacc and cBioportal are: (1) OSacc can help users to limit the analysis in a subgroup of patients by selecting the factors including age, gender and TNM, but cBioportal cannot do this; (2) OSacc can analyze the prognostic significance of interesting gene using different cutoffs including median, quartile and trichotomy of the expression level, while cBioportal just has median cutoff; (3) cBioportal just used the single dataset TCGA-ACC for genes’ survival analysis while OSacc integrated TCGA and GEO datasets for prognosis analysis. However, there are limitations for OSacc. For example, although combing seven datasets into one pooled analysis can enlarge the number of ACC patients, the quite large differences in overall survival across the studies or heterogeneity in tissue source or different analysis platform might be questioned in the interpretation of prognosis analysis results.</p>
    <p>To our knowledge, OSacc is the largest ACC dataset for ACC prognosis analysis. Although the current sample size is only 268 ACC samples available, we will keep adding more ACC data into OSacc database and update the functionality when new ACC expression profiling dataset is available.</p>
  </sec>
  <sec id="S0005">
    <title>Conclusion</title>
    <p>OSacc is a free, publicly accessible web tool allowing biomedical researchers and clinicians lacking bioinformatics training to easily analyze the prognostic potency of the genes of interest in ACC.</p>
  </sec>
</body>
<back>
  <ack>
    <title>Acknowledgments</title>
    <p>This study is supported by Innovative National Natural Science Foundation of China (No.81602362), supporting grants of Henan University (no. 2015YBZR048; no. B2015151), Yellow River Scholar Program (no. H2016012), and Program for Innovative Talents of Science and Technology in Henan Province (no. 18HASTIT048), Projects for College Students in Henan University (no. 201819002), China Postdoctoral Science Foundation (no. 2017M62237) and Henan Postdoctoral Foundation (no. 001702052), Program for Science and Technology Development in Henan Province (no.162102310391, no.172102210187), Program for Scientific and Technological Research of Henan Education Department (no.14B520022), Program for Young Key Teacher of Henan Province (2016GGJS-214), Kaifeng Science and Technology Major Project (18ZD008), supporting grant of Bioinformatics Center of Henan University (no. 2018YLJC01). Longxiang Xie and Qiang Wang are co-first authors.</p>
  </ack>
  <sec id="S0006" sec-type="COI-statement">
    <title>Disclosure</title>
    <p> The authors report no conflicts of interest in this work.</p>
  </sec>
  <ref-list>
    <title>References</title>
    <ref id="CIT0001">
      <label>1.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Allolio</surname><given-names>B</given-names></string-name>, <string-name><surname>Fassnacht</surname><given-names>M</given-names></string-name>. <article-title>Adrenocortical carcinoma: clinical update</article-title>. <source><italic toggle="yes">Int J Clin Endocrinol Metab</italic></source>. <year>2006</year>;<volume>91</volume>:<fpage>2027</fpage>–<lpage>2037</lpage>. doi:<pub-id pub-id-type="doi">10.1210/jc.2005-2639</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0002">
      <label>2.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Libé</surname><given-names>R</given-names></string-name>. <article-title>Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment</article-title>. <source><italic toggle="yes">Front Cell Dev Biol</italic></source>. <year>2015</year>;<volume>3</volume>:<fpage>45</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fcell.2015.00045</pub-id><pub-id pub-id-type="pmid">26191527</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0003">
      <label>3.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Xie</surname><given-names>L</given-names></string-name>, <string-name><surname>Dang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Guo</surname><given-names>J</given-names></string-name>, et al. <article-title>High KRT8 expression independently predicts poor prognosis for lung adenocarcinoma patients</article-title>. <source><italic toggle="yes">Genes</italic></source>. <year>2019</year>;<volume>10</volume>:<fpage>36</fpage>. doi:<pub-id pub-id-type="doi">10.3390/genes10010036</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0004">
      <label>4.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Ludwig</surname><given-names>JA</given-names></string-name>, <string-name><surname>Weinstein</surname><given-names>JN</given-names></string-name>. <article-title>Biomarkers in cancer staging, prognosis and treatment selection</article-title>. <source><italic toggle="yes">Nat Rev Cancer</italic></source>. <year>2005</year>;<volume>5</volume>:<fpage>845</fpage>. doi:<pub-id pub-id-type="doi">10.1038/nrc1739</pub-id><pub-id pub-id-type="pmid">16239904</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0005">
      <label>5.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Aguirre-Gamboa</surname><given-names>R</given-names></string-name>, <string-name><surname>Gomez-Rueda</surname><given-names>H</given-names></string-name>, <string-name><surname>Martínez-Ledesma</surname><given-names>E</given-names></string-name>, et al. <article-title>SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis</article-title>. <source><italic toggle="yes">PLoS ONE</italic></source>. <year>2013</year>;<volume>8</volume>:<fpage>e74250</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0074250</pub-id><pub-id pub-id-type="pmid">24066126</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0006">
      <label>6.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Wang</surname><given-names>F</given-names></string-name>, <string-name><surname>Yan</surname><given-names>Z</given-names></string-name>, <string-name><surname>Lv</surname><given-names>J</given-names></string-name>, et al. <article-title>Gene expression profiling reveals distinct molecular subtypes of esophageal squamous cell carcinoma in Asian populations</article-title>. <source><italic toggle="yes">Neoplasia</italic></source>. <year>2019</year>;<volume>21</volume>:<fpage>571</fpage>–<lpage>581</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neo.2019.03.013</pub-id><pub-id pub-id-type="pmid">31048097</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0007">
      <label>7.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Fenske</surname><given-names>W</given-names></string-name>, <string-name><surname>Voelker</surname><given-names>H-U</given-names></string-name>, <string-name><surname>Adam</surname><given-names>P</given-names></string-name>, et al. <article-title>Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma</article-title>. <source><italic toggle="yes">Endocr Relat Cancer</italic></source>. <year>2009</year>;<volume>16</volume>:<fpage>919</fpage>. doi:<pub-id pub-id-type="doi">10.1677/ERC-08-0211</pub-id><pub-id pub-id-type="pmid">19465749</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0008">
      <label>8.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Demeure</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Coan</surname><given-names>KE</given-names></string-name>, <string-name><surname>Grant</surname><given-names>CS</given-names></string-name>, et al. <article-title>PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target</article-title>. <source><italic toggle="yes">Surgery</italic></source>. <year>2013</year>;<volume>154</volume>:<fpage>1405</fpage>–<lpage>1416</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.surg.2013.06.058</pub-id><pub-id pub-id-type="pmid">24238056</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0009">
      <label>9.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name><surname>Xie</surname><given-names>L</given-names></string-name>, <string-name><surname>Dang</surname><given-names>Y</given-names></string-name>, et al. <article-title>OSlms: a web server to evaluate the prognostic value of genes in leiomyosarcoma</article-title>. <source><italic toggle="yes">Front Oncol</italic></source>. <year>2019</year>;<volume>9</volume>.</mixed-citation>
    </ref>
    <ref id="CIT0010">
      <label>10.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Xie</surname><given-names>L</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name><surname>Dang</surname><given-names>Y</given-names></string-name>, et al. <article-title>OSkirc: a web tool for identifying prognostic biomarkers in kidney renal clear cell carcinoma</article-title>. <source><italic toggle="yes">Future Oncol</italic></source>. <year>2019</year>. doi:<pub-id pub-id-type="doi">10.2217/fon-2019-0296</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0011">
      <label>11.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Zhang</surname><given-names>G</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name><surname>Yang</surname><given-names>M</given-names></string-name>, et al. <article-title>OSblca: a web server for investigating prognostic biomarkers of bladder cancer patients</article-title>. <source><italic toggle="yes">Front Oncol</italic></source>. <year>2019</year>;<volume>9</volume>. doi:<pub-id pub-id-type="doi">10.3389/fonc.2019.00466</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0012">
      <label>12.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name><surname>Wang</surname><given-names>F</given-names></string-name>, <string-name><surname>Lv</surname><given-names>J</given-names></string-name>, et al. <article-title>Interactive online consensus survival tool for esophageal squamous cell carcinoma prognosis analysis</article-title>. <source><italic toggle="yes">Oncol Lett</italic></source>. <year>2019</year>;<volume>18</volume>:<fpage>1199</fpage>–<lpage>1206</lpage>. doi:<pub-id pub-id-type="doi">10.3892/ol.2019.10440</pub-id><pub-id pub-id-type="pmid">31423180</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0013">
      <label>13.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name><surname>Yan</surname><given-names>Z</given-names></string-name>, et al. <article-title>OScc: an online survival analysis web server to evaluate the prognostic value of biomarkers in cervical cancer</article-title>. <source><italic toggle="yes">Future Oncol</italic></source>. <year>2019</year>. doi:<pub-id pub-id-type="doi">10.2217/fon-2019-0412</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0014">
      <label>14.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Dai</surname><given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name><surname>Zeng</surname><given-names>T</given-names></string-name>, et al. <article-title>Characterization of the oncogenic function of centromere protein F in hepatocellular carcinoma</article-title>. <source><italic toggle="yes">Biochem Biophys Res Commun</italic></source>. <year>2013</year>;<volume>436</volume>:<fpage>711</fpage>–<lpage>718</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbrc.2013.06.021</pub-id><pub-id pub-id-type="pmid">23791740</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0015">
      <label>15.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Shahid</surname><given-names>M</given-names></string-name>, <string-name><surname>Lee</surname><given-names>MY</given-names></string-name>, <string-name><surname>Piplani</surname><given-names>H</given-names></string-name>, et al. <article-title>Centromere protein F (CENPF), a microtubule binding protein, modulates cancer metabolism by regulating pyruvate kinase M2 phosphorylation signaling</article-title>. <source><italic toggle="yes">Cell Cycle</italic></source>. <year>2018</year>;<volume>17</volume>:<fpage>2802</fpage>–<lpage>2818</lpage>. doi:<pub-id pub-id-type="doi">10.1080/15384101.2018.1557496</pub-id><pub-id pub-id-type="pmid">30526248</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0016">
      <label>16.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Shahid</surname><given-names>M</given-names></string-name>, <string-name><surname>Kim</surname><given-names>M</given-names></string-name>, <string-name><surname>Lee</surname><given-names>MY</given-names></string-name>, et al. <article-title>Downregulation of CENPF remodels prostate cancer cells and alters cellular metabolism</article-title>. <source><italic toggle="yes">Proteomics</italic></source>. <year>2019</year>;<fpage>1900038</fpage>. doi:<pub-id pub-id-type="doi">10.1002/pmic.v19.11</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0017">
      <label>17.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Goswami</surname><given-names>CP</given-names></string-name>, <string-name><surname>Nakshatri</surname><given-names>H</given-names></string-name>. <article-title>PROGgeneV2: enhancements on the existing database</article-title>. <source><italic toggle="yes">BMC Cancer</italic></source>. <year>2014</year>;<volume>14</volume>:<fpage>970</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1471-2407-14-970</pub-id><pub-id pub-id-type="pmid">25518851</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0018">
      <label>18.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Anaya</surname><given-names>J</given-names></string-name>. <article-title>OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs</article-title>. <source><italic toggle="yes">PeerJ Comput Sci</italic></source>. <year>2016</year>;<volume>2</volume>:<fpage>e67</fpage>. doi:<pub-id pub-id-type="doi">10.7717/peerj-cs.67</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0019">
      <label>19.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Gao</surname><given-names>J</given-names></string-name>, <string-name><surname>Aksoy</surname><given-names>BA</given-names></string-name>, <string-name><surname>Dogrusoz</surname><given-names>U</given-names></string-name>, et al. <article-title>Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal</article-title>. <source><italic toggle="yes">Sci Signal</italic></source>. <year>2013</year>;<volume>6</volume>:<fpage>pl1</fpage>. doi:<pub-id pub-id-type="doi">10.1126/scisignal.2004088</pub-id><pub-id pub-id-type="pmid">23550210</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0020">
      <label>20.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Giordano</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Kuick</surname><given-names>R</given-names></string-name>, <string-name><surname>Else</surname><given-names>T</given-names></string-name>, et al. <article-title>Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling</article-title>. <source><italic toggle="yes">Clin Cancer Res</italic></source>. <year>2009</year>;<volume>15</volume>:<fpage>668</fpage>–<lpage>676</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-1067</pub-id><pub-id pub-id-type="pmid">19147773</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0021">
      <label>21.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Heaton</surname><given-names>JH</given-names></string-name>, <string-name><surname>Wood</surname><given-names>MA</given-names></string-name>, <string-name><surname>Kim</surname><given-names>AC</given-names></string-name>, et al. <article-title>Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin</article-title>. <source><italic toggle="yes">Am J Pathol</italic></source>. <year>2012</year>;<volume>181</volume>:<fpage>1017</fpage>–<lpage>1033</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ajpath.2012.05.026</pub-id><pub-id pub-id-type="pmid">22800756</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0022">
      <label>22.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Assié</surname><given-names>G</given-names></string-name>, <string-name><surname>Letouzé</surname><given-names>E</given-names></string-name>, <string-name><surname>Fassnacht</surname><given-names>M</given-names></string-name>, et al. <article-title>Integrated genomic characterization of adrenocortical carcinoma</article-title>. <source><italic toggle="yes">Nat Genet</italic></source>. <year>2014</year>;<volume>46</volume>:<fpage>607</fpage>. doi:<pub-id pub-id-type="doi">10.1038/ng.2895</pub-id><pub-id pub-id-type="pmid">24747642</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0023">
      <label>23.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Pinto</surname><given-names>EM</given-names></string-name>, <string-name><surname>Rodriguez-Galindo</surname><given-names>C</given-names></string-name>, <string-name><surname>Choi</surname><given-names>JK</given-names></string-name>, et al. <article-title>Prognostic significance of major histocompatibility complex class II expression in pediatric adrenocortical tumors: a St. Jude and Children’s Oncology Group Study</article-title>. <source><italic toggle="yes">Clin Cancer Res</italic></source>. <year>2016</year>;<volume>22</volume>:<fpage>6247</fpage>–<lpage>6255</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-2738</pub-id><pub-id pub-id-type="pmid">27307598</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0024">
      <label>24.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Zheng</surname><given-names>S</given-names></string-name>, <string-name><surname>Verhaak</surname><given-names>RGW</given-names></string-name>, <string-name><surname>Giordano</surname><given-names>TJ</given-names></string-name>, et al. <article-title>Comprehensive pan-genomic characterization of adrenocortical carcinoma</article-title>. <source><italic toggle="yes">Cancer Cell</italic></source>. <year>2016</year>;<volume>29</volume>:<fpage>723</fpage>–<lpage>736</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ccell.2016.04.002</pub-id><pub-id pub-id-type="pmid">27165744</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0025">
      <label>25.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Pinheiro</surname><given-names>C</given-names></string-name>, <string-name><surname>Granja</surname><given-names>S</given-names></string-name>, <string-name><surname>Longatto-Filho</surname><given-names>A</given-names></string-name>, et al. <article-title>Metabolic reprogramming: a new relevant pathway in adult adrenocortical tumors</article-title>. <source><italic toggle="yes">Oncotarget</italic></source>. <year>2015</year>;<volume>6</volume>:<fpage>44403</fpage>. doi:<pub-id pub-id-type="doi">10.18632/oncotarget.5623</pub-id><pub-id pub-id-type="pmid">26587828</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0026">
      <label>26.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Liu-Chittenden</surname><given-names>Y</given-names></string-name>, <string-name><surname>Patel</surname><given-names>D</given-names></string-name>, <string-name><surname>Gaskins</surname><given-names>K</given-names></string-name>, et al. <article-title>Serum RARRES2 is a prognostic marker in patients with adrenocortical carcinoma</article-title>. <source><italic toggle="yes">Int J Clin Endocrinol Metab</italic></source>. <year>2016</year>;<volume>101</volume>:<fpage>3345</fpage>–<lpage>3352</lpage>. doi:<pub-id pub-id-type="doi">10.1210/jc.2016-1781</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0027">
      <label>27.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Patel</surname><given-names>D</given-names></string-name>, <string-name><surname>Ellis</surname><given-names>R</given-names></string-name>, <string-name><surname>Howard</surname><given-names>B</given-names></string-name>, et al. <article-title>Analysis of IGF and IGFBP as prognostic serum biomarkers for adrenocortical carcinoma</article-title>. <source><italic toggle="yes">Ann Surg Oncol</italic></source>. <year>2014</year>;<volume>21</volume>:<fpage>3541</fpage>–<lpage>3547</lpage>. doi:<pub-id pub-id-type="doi">10.1245/s10434-014-3768-5</pub-id><pub-id pub-id-type="pmid">24833102</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0028">
      <label>28.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Kwok</surname><given-names>GT</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>JT</given-names></string-name>, <string-name><surname>Glover</surname><given-names>AR</given-names></string-name>, et al. <article-title>Treatment and management of adrenal cancer in a specialized Australian endocrine surgical unit: approaches, outcomes and lessons learnt</article-title>. <source><italic toggle="yes">ANZ J Surg</italic></source>. <year>2019</year>;<volume>89</volume>:<fpage>48</fpage>–<lpage>52</lpage>. doi:<pub-id pub-id-type="doi">10.1111/ans.15032</pub-id><pub-id pub-id-type="pmid">30710432</pub-id></mixed-citation>
    </ref>
    <ref id="CIT0029">
      <label>29.</label>
      <mixed-citation publication-type="journal"><string-name><surname>Duregon</surname><given-names>E</given-names></string-name>, <string-name><surname>Molinaro</surname><given-names>L</given-names></string-name>, <string-name><surname>Volante</surname><given-names>M</given-names></string-name>, et al. <article-title>Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma</article-title>. <source><italic toggle="yes">Mod Pathol</italic></source>. <year>2014</year>;<volume>27</volume>:<fpage>1246</fpage>. doi:<pub-id pub-id-type="doi">10.1038/modpathol.2013.230</pub-id><pub-id pub-id-type="pmid">24434900</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
